Beraprost

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Beraprost
Beraprost.svg
Systematic (IUPAC) name
2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-
methyl-1-octen-6-ynyl)-1H-cyclopenta(b)benzofuran-
5-butanoic acid
Clinical data
AHFS/Drugs.com International Drug Names
Legal status
  •  ?
Routes Oral
Pharmacokinetic data
Bioavailability 50–70%
Metabolism Unknown
Half-life 35–40 minutes
Excretion ?
Identifiers
CAS number 88430-50-6 88475-69-8
ATC code B01AC19
PubChem CID 5282428
IUPHAR ligand 1967
ChemSpider 5293169 YesY
UNII 35E3NJJ4O6 YesY
ChEMBL CHEMBL1207745
Chemical data
Formula C24H30O5 
Mol. mass 398.492 g/mol
 YesY (what is this?)  (verify)

Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.

Clinical pharmacology[edit]

As an analogue of prostacyclin PGI2, beraprost effects vasodilation, which in turn lowers the blood pressure. Beraprost also inhibits platelet aggregation, though the role this phenomenon may play in relation to pulmonary hypertension has yet to be determined.

Dosage and administration[edit]

Beraprost is administered orally as a pill.